ESMO 2022

Simple and cheap surgical technique may impact survival…

Long-term data on dose density therapy in chemotherapy

Endocrine response in eBC

Immuntherapy only for low risk patients?

Reduction of peripheral neuropathy with taxane therapy

Hand cooling and compression both effective in…

Dose-dense standard of care is the optimal care

Consolidating data from prospective studies

QoL and longterm toxicity

Roadmap for the adjuvant setting

Dose dense is better

My highlights of ESMO22

DD is the champion!

I miei punti salienti di ESMO22

Il vincitore e’ il dose dense!!

Chłodzenie rąk i terapia kompresyjna skutecznie…

Datele trialurilor se consolideata

Rosta i tania technika chirurgiczna może wpływać na…

DATA: Still open questions on the optimal duration of…

Unmeet needs and my wishes for 2022!

How to deal with the negative SERD data?

Dose-dense CT Efficacy confirmed in the Nodal+ ER+…

Tailoring Adjuvant Therapy

Status update - adjuvant IO. Are TILs prognostic?

New data re-inforces SG as a new option pre-treated…

Another option for heavily pre-treated HR+ advanced…

HER2+ and still without chemotherapy

New treatment option for heavily pre-treated patients…

More therapy options for patients with HR+, HER2+…

My highlights of ESMO22

The third in the bunch

Survival benefit from SG in mBC

Discontinued development

Negative and yet positive?!

Exciting data, but Phase 3 studies are needed

Sacituzumab govitecan for everybody!

SG is a novel treatment option for HR+/HER2- disease

Interim analysis shows promising data on Abema in the…

Survival benefit in endocrine sensitive patients

ADC after ADC - is there any orientation?

CDK4/6i could be an option for selected ER+/HER2+…

TROPiCS-02 highlights

Update on biomarkers on ADCs of the DAISY trial

VEX has no place in chemotherapy of metastatic breast…

Endocrine-based therapy may prove more effective than…

Nouvelle option thérapeutique pour les patientes…

Sacituzumab Govitecan: Un farmaco per tutte?

Nouvelles données des analyses expolratoires dans…

Survie globale pas encore significative statistiquement…

Nuove opzioni di trattamento personalizzate per…

TROPiCS-02 highlights

Leczenie zaawansowanych raków „potrójnie dodatnich”…

Sopravvivenza globale nello studio MONARCH3

SG come nuova opzione di cura Per pazienti con tumore…

Interim OS Data & PFS Update for Abemaciclib hint…

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd…

CDK4/6i plus Trastuzumab – a possible chemo-free option…

ADC efficacy in perspective: SG overall survival…

Monarch-3: strong OS Survival; DAWNA-2: PFS in line…

Pollution and lung cancer - one mechanism revealed

Long term follow-up of ADAURA trial

Is OS really needed?

Neoadjuvant strategies for PD-L1 < 1 %

Window for treatment selection

INCREASE - to good to be true?

Liquid biopsy monitoring of EGFR-mutant lung cancer…

ADAURA revisited

Concurrent preoperative IO/CRT in early lung cancer

Osimertinib stays standard adjuvant

Double IO + chemoradiotherapy - is it feasible in…

Osimertinib - curing or delaying relapse?

Pollution et cancer du poumon - un mécanisme mis en…

Eine Plattform für "take the winner"-Strategie

Osimertinib: una cura o ritarda la ripresa di malattia?

Langzeitdaten ADAURA

Dubbele immunotherapie plus chemoradiotherapie - is het…

ADAURA revisited

Osimertinib bleibt Standard adjuvant

DFS matters!

Can IO be discontinued?

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Sotorasib - a new standard of care?

If you don't look, vou don't find - once you found it,…

Immunotherapy in unfit population? Perhaps...

The journey at KRAS G12C continues

Sotorasib: sweet and sour results

New immunotherapy options for pts. ineligible to 1st…

Can we finally treat poor prognostic patients with…

Chemoimmunotherapy - improvement of survival after 5…

A new step in treatment of KRAS G12C mutant NSCLC

One more brick in the KRAS G12C wall

Duration of immunotherapy : Stop and go strategy for…

Pneumonitis and T-DXd

Question about timing and duration of immunotherapy…

Is shorter immunotherapy equally effective and less…

Real-world data on Atezolizumab

Cemiplimab beyond progression?

Poseidon and STK11/KEAP

Emerging IO mono options in the first line

HER2 - the next actionable mutation in lung cancer?

Liquid biopsy monitoring in treatment decisions

New therapy combination after progression on 1L…

5-year data on survival under immunotherapy

Induction chemoimmunotherapy in borderline…

DESTINY-Lung02 - better than the original?

Preview on lung cancer highlights

Atezolizumab better than vinorelbin in reduced…

5 years of chemoimmunotherapy: solid grounded

5-year update on 1st line chemoimmunotherapy

Liquid Biopsy Monitoring zur Therapiesteuerung

Poseidon und STK11/KEAP

IO-IO neoadjuvant bei PD-L1 neg.

Chimio-immunothérapie - amélioration de la survie après…

Sotorasib vs. Docetaxel bei mKRAS G12C

Cemiplimab beyond progression?

Una nueva opción de tratamiento con IO en pacientes no…

Neue Therapiekombination in der Resistenz nach…

Un mattone in piu' nel muro del KRAS G12C

Kann IO pausiert werden?

Die Reise bei KRAS G12C geht weiter

Kunnen we eindelijk patiënten met een slechte prognose…

5 Jahre Chemo-Immuntherapie: starker Effekt

Les études incontournables à l’ESMO 2022

Une nouvelle étape dans le traitement du CBNPC KRAS…

5-Jahresüberleben mit Immuntherapie

Resultados Agridulces de Sotorasib

Durée de l'immunothérapie : stratégie Stop and Go pour…

Se non lo cerchi non lo troiv. Quando lo hai trovato,…

Données de vie réelle avec l’atezolizumab

Pneumonitis und T-DXd

Neue Option der IO-Therapie in der Erstlinie

Kürzere Immuntherapie gleich effektiv aber weniger…

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

Immunoterapia nella popolazione non fit: forse

A positive study! With a question mark?

Novel data and long-term efficacy of chemo-IO in mNSCLC

Heterogenity in the genetic landscape - little progress…

More questions being raised

Adjuvant Immuntherapy in kidney cancer

No value of IPI/Nivo in the adjuvant setting.

New combo - triplet therapy for kidney cancer

Place of triplet therapy

News in terms of adjuvant

Two negative studies question adjuvant approach in RCC

Exciting data for high-risk patients: is this the start…

Brief highlights about RCC & urothelial cancer from…

Adjuvant CPI in kidney cancer – 2 phase III trials with…

Tratamiento perioperatorio con immunoterapia en cáncer…

Terapia triple para cancer renales

Inmunoterapia adyuvante en el cancer renales

Shedding light on TKI/Checkpointinhibitor combinations

Therapy combinations in RCC - what is the role of…

Immunomodulation in combination with…

Brief highlights about RCC & urothelial cancer from…

EV + Pembro with excellent response rates

Biomarker exploration in urothelial cancer - finding…

Adjuvant and neoadjuvant therapy approaches in…

PSA at 8-months as a biomarker

Cabazitaxel better tolerated in elderly men

Radicals - ADT & Radiotherapy

ADT + ENZA better choice than monotherapy

Optimizing cabazitaxel chemotherapy

QoL data from ARASENS triplet therapy study mHRPC

Should intensification of ADT be considered in…

IM arbiraterone decanoate might demonstrate superior…

Length of hormone therapy after radiation

In older vulnerable - less is more

Update on the PROpel study

Combination of olaparib leads to promising results

ADCs - a possible therapeutic approach

Genetic testing before PARP therapy is useful

Further evaluation of PSA correlates

Biomarker data for better patients selection

Triplet therapy with darolutamide in prostate cancer

Uppdatering i PROpel studien

Livskvalitetsuppföljning i ARASENS studien

Which men benefit from adding ADT?

Positive results, but testing not that simple

Modern Imaging is the new standard

PSA response after triplet therapy: What is the impact…

Addition of CPI to Radiochemotherapy in LA-HNSCC?

TILs - Fashion is the eternal return of the old

Novel approach von Biontech towards Cancer – game…

New group of substances for rare diseases

IAP-inhibition – comming game changer in LA-HNSCC…